Advanced Symptom Palliation Through Integrated Relief Engagement

Condition(s) studied

Investigational drug(s) / intervention(s)

Advanced cancer patients' palliative symptoms management using Beacon analysis of patient-provided of objective and subjective data: The study intervention consists of palliative standard of care treatment, including a comprehensive data collection regarding the patient's biopsychosocial status using Beacon digital platform, which aggregates patients' provided data. Data includes objective, continuously recorded physiological parameters using wearables and smartphones, while subjective data consists of written and vocal patient-reported outcome measures.

Study summary

Beacon is a digital platform that processes objective and subjective aggregated data provided by patients. Objective data is provided by standard wearables, while subjective data is provided by patient-reported outcome measures (PROMs), comprising written and vocal patient reporting.

The ASPIRE.AI study is a prospective study evaluating the feasibility of clinicians' use of aggregated data that was provided by patients and analyzed through "Beacon", and its influence on advanced cancer patients' palliative symptoms management.

Approximately 40 consecutive eligible ambulatory advanced cancer patients first attending the palliative unit in the Davidoff Center will be enrolled. The trial will continue for \~1 year, with each patient participating in this trial for a total of about 12 weeks.

All participants will receive the intervention. The intervention comprises the palliative standard of care treatment along with the usage of the Beacon digital platform, which enables comprehensive data collection and aggregation regarding the patient's biopsychosocial status, and thus, the patient's symptom burden.

Data collected and aggregated through Beacon includes Beacon data provided by the patients via wearables (smartwatch/sensors), smartphones, and written and recorded PROMs.

Researchers will then evaluate physician engagement with the platform, Influence on treatment, and the physician user experience rating as well as patients' adherence, satisfaction with Beacon usage, and changes in patients' symptom burden and quality of life.

Eligibility

Primary outcome measure(s)

• The number of physician's login into the Beacon platform, per patient, throughout the 12-week study period. — Throughout the 12-week study period.
• Percent of clinical palliative care encounters involving the use of the Beacon platform throughout the 12-week study. — Throughout the 12-week study
• The number of fields reviewed by the physician per login to the Beacon platform throughout the 12-week study period. — Throughout the 12-week study period.
• Beacon platform fields rating according to the physicians' reviewing frequency. — Throughout the 12-week study.
• Physicians' rating of the Beacon-derived data contribution to clinical treatment decision-making/planning following each clinical encounter utilizing the Beacon platform. — Throughout the 12-week study period.
  Assessed according to a study-specific questionnaire, completed by the physicians following each patient's encounter.

Trial sites (1)

Other trials for the same condition